Back
Full-text
Journal article

The Role of Long Non-Coding RNAs in Hepatocarcinogenesis.

  • Lanzafame M Institute of Pathology, University Hospital Basel, 4031 Basel, Switzerland. manuela.lanzafame@usb.ch.
  • Bianco G Institute of Pathology, University Hospital Basel, 4031 Basel, Switzerland. gaia.bianco@usb.ch.
  • Terracciano LM Institute of Pathology, University Hospital Basel, 4031 Basel, Switzerland. luigi.terracciano@usb.ch.
  • Ng CKY Institute of Pathology, University Hospital Basel, 4031 Basel, Switzerland. kiuyancharlotte.ng@usb.ch.
  • Piscuoglio S Institute of Pathology, University Hospital Basel, 4031 Basel, Switzerland. salvatore.piscuoglio@usb.ch.
  • 2018-03-03
Published in:
  • International journal of molecular sciences. - 2018
carcinogenesis
hepatocellular carcinoma
liver cancer
long non-coding RNA
Animals
Biomarkers, Tumor
Carcinoma, Hepatocellular
Cell Transformation, Neoplastic
Epithelial-Mesenchymal Transition
Gene Expression Regulation, Neoplastic
Genetic Therapy
Humans
Liver Neoplasms
Molecular Diagnostic Techniques
Prognosis
RNA Interference
RNA, Antisense
RNA, Long Noncoding
English Whole-transcriptome analyses have revealed that a large proportion of the human genome is transcribed in non-protein-coding transcripts, designated as long non-coding RNAs (lncRNAs). Rather than being "transcriptional noise", increasing evidence indicates that lncRNAs are key players in the regulation of many biological processes, including transcription, post-translational modification and inhibition and chromatin remodeling. Indeed, lncRNAs are widely dysregulated in human cancers, including hepatocellular carcinoma (HCC). Functional studies are beginning to provide insights into the role of oncogenic and tumor suppressive lncRNAs in the regulation of cell proliferation and motility, as well as oncogenic and metastatic potential in HCC. A better understanding of the molecular mechanisms and the complex network of interactions in which lncRNAs are involved could reveal novel diagnostic and prognostic biomarkers. Crucially, it may provide novel therapeutic opportunities to add to the currently limited number of therapeutic options for HCC patients. In this review, we summarize the current status of the field, with a focus on the best characterized dysregulated lncRNAs in HCC.
Language
  • English
Open access status
gold
Identifiers
Persistent URL
https://folia.unifr.ch/global/documents/232257
Statistics
Document views: 56 File downloads:
  • Full-text: 0